162
Participants
Start Date
January 31, 2017
Primary Completion Date
December 31, 2018
Study Completion Date
May 31, 2020
A-dmDT390-bisFv(UCHT1)
anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
Vorinostat
ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
Lead Sponsor
City of Hope National Medical Center
OTHER
Columbia University
OTHER
Dana-Farber Cancer Institute
OTHER
Northwestern University Feinberg School of Medicine
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Ohio State University Comprehensive Cancer Center
OTHER
Rush University Medical Center
OTHER
Scott and White Hospital & Clinic
OTHER
Yale University
OTHER
Stanford University
OTHER
Thomas Jefferson University
OTHER
University of Arkansas
OTHER
University of Colorado, Denver
OTHER
University of Texas Southwestern Medical Center
OTHER
University of Washington
OTHER
Vanderbilt University School of Medicine
OTHER
Washington University School of Medicine
OTHER
Angimmune LLC
INDUSTRY